Pyxis slides after new Phase 1 trial data for lead MICVO option
Pyxis Oncology (PYXS) fell more than 13% in premarket trading after Phase 1 early-stage data for micvotabart pelidotin (MICVO) as a late-line option for certain head and neck carcinoma.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.